Aimedis sets a milestone in the medical sector

The blockchain-based medical start-up Aimedis can for the first time distribute an external study via its own NFT marketplace as part of a partnership.

As of 2012 “Brain on Fire” appeared, Susannah Cahalan gained global attention. The journalist of New York Post described in the autobiography her story of suffering with a rare form of encephalitis (Anti-NMDA receptor encephalitis). The autoimmune disease forced your body to produce antibodies against the NMDA receptor, a protein that plays an important role in transmitting signals in the brain. As a result, Cahalan developed numerous symptoms: from loss of appetite and insomnia, through delusions and memory loss, to epileptic seizures.

The career of the then 21-year-old was marked by false diagnoses: from “partying too much” to dementia and schizophrenia. It was only when the young journalist asked for treatment from the neurologist Dr. Souhel Najjar, the neurologist was able to correctly assess the clinical picture and then initiate therapy methods that helped Cahalan to make a full recovery. At the time, she was only the 217th patient documented to suffer from the rare form of encephalitis. Her book helped increase the number of successful diagnoses of the disease.

Orphan Disease: the poor child of the pharmaceutical industry

This case exemplifies a problem in the medical sector that experts generally call “Orphan Disease” respectively “Rare Disease” describe. These are extremely rare diseases that in most cases cannot be treated properly because either the appropriate drugs do not exist or are still being developed. For the pharmaceutical industry, however, research in this field makes little sense from an economic point of view, since the research and production costs significantly exceed the expected sales. And although there are already initiatives and even laws like that on the part of the state Orphan Drug Act (1983) or the EUOrdinance on medicinal products for the treatment of orphan diseases (2000) reports, few breakthroughs have been celebrated in this medical field.

How Aimedis is transforming healthcare

The blockchain-based medical start-up Aimedis wants to tackle this issue, among other things. The company from the Netherlands and the United Arab Emirates would like to simplify and improve the structuring, protection and monetization of scientific and medical data. Data packages filled with studies, certificates, disease histories and other information should be treated and monetized as intellectual property in the age of digitization. In the future, a platform is to be created in which doctors, patients, research institutes and insurance companies can not only exchange data, but also earn an equal amount from it. In the case of Susannah Cahalan, such a platform would likely have resulted in a much faster diagnosis.

Aimedis relies on two draft horses: non-fungible tokens and the native AIMX token. While the data is available as NFT to the individual network participants via their own marketplace, AIMX acts as the platform’s means of payment. Although users can pay for data packages in fiat currencies, there are advantages to using the native platform currency. There are not only discounts on certain transactions, but also a staking function.

Of the maximum 600 million AIMx, 60 million AIMx are currently available for institutional and private investors as of October 19 for sale. On the same day, there is also a listing on the decentralized crypto exchange PancakeSwap.

Aimedis sets up cancer study as NFT

In addition, can Aimedis are already enjoying their first major successes. The company will soon be distributing a first multi-center, cross-border cancer study by an external partner via the NFT marketplace. Aimedis prepares the anonymized medical data in a structured and traceable manner – regardless of the pharmaceutical industry. The study is financed purely through NFT sales. CEO Michael Kaldasch says:

This is the foundation of a new kind of medicine and research. Finally, studies can now also be carried out that the pharmaceutical industry would never consider due to a lack of profitability. In addition, with our platform we also address the challenges that medicine is faced with in times of digitization and big data.

Michael Kaldasch, CEO of Aimedis

Prof. Dr. Timo Schinköthe with his company Cankado involved in the project and also on the advisory board Aimedis, also sees great opportunities in the project to establish a completely new type of pharmaceutical and clinical research. “With the Aimedis With the NFT concept we can break new ground, the jointly planned study is just the beginning. “

Furthermore, the vision of Aimedis also found acceptance in the financial sector. Just recently announced the blockchain-based medical start-up has partnered with Nonce VC, one of the leading venture capital in the field of blockchain financing. Aimedis hopes that the financial company, which is well networked in blockchain circles, will not only provide growth strategies and additional capital, but also technical support. In the past could Nonce VC already providing start-up assistance to several start-ups.